Inventor · disambiguated record
Kai W. Wucherpfennig
Also filed as: WUCHERPFENNIG KAI · WUCHERPFENNIG KAI W
20 granted patents·12 pending applications·108 citations·filing 1995–2024
93Inventor score
Files withDANA FARBER CANCER INST INC18HARVARD COLLEGE3BRIGHAM & WOMENS HOSPITAL1BROAD INST INC1CHILDRENS MEDICAL CENTER1
Top patents by PatentIndex Score
32 records- 0194US11597934B2Methods and compositions for reducing immunosuppression by tumor cellsDANA FARBER CANCER INST INC·Filed 2020·Granted Mar 7, 2023·3 cites·20 claims
- 0291US10876120B2Methods and compositions for reducing immunosupression by tumor cellsDANA FARBER CANCER INST INC·Filed 2018·Granted Dec 29, 2020·5 cites·9 claims
- 0390US11459389B2Monoclonal antibodies that bind human CD161MASSACHUSETTS INST TECHNOLOGY·Filed 2020·Granted Oct 4, 2022·3 cites·16 claims
- 0488US9944931B2Methods and compositions for reducing immunosupression by tumor cellsDANA FARBER CANCER INST INC·Filed 2014·Granted Apr 17, 2018·11 cites·11 claims
- 0588US9402905B2Therapeutic peptidesDANA FARBER CANCER INST INC·Filed 2013·Granted Aug 2, 2016·14 cites·24 claims
- 0683US5874531AIdentification of self and non-self antigens implicated autoimmune diseaseHARVARD COLLEGE·Filed 1995·Granted Feb 23, 1999·43 cites·4 claims
- 0782US11820822B2Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathwaysDANA FARBER CANCER INST INC·Filed 2018·Granted Nov 21, 2023·1 cites·6 claims
- 0880US10793633B2Therapeutic peptidesDANA FARBER CANCER INST INC·Filed 2016·Granted Oct 6, 2020·2 cites·3 claims
- 0980US10106611B2Antibodies that bind to MHC class I polypeptide-related sequence ADANA FARBER CANCER INST INC·Filed 2014·Granted Oct 23, 2018·5 cites·36 claims
- 1079US2023383298A1Methods and Compositions for Reducing Immunosupression by Tumor CellsDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 1174US2024092904A1Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathwaysDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 1273US11421032B2Compositions and methods for inhibition of MICA/B sheddingDANA FARBER CANCER INST INC·Filed 2018·Granted Aug 23, 2022·1 cites·16 claims
- 1371US8314210B2Compositions and methods for the generation of MHC class II compounds by peptide exchangeWUCHERPFENNIG KAI W·Filed 2003·Granted Nov 20, 2012·8 cites·6 claims
- 1471US8148084B2Diagnosis of autoimmune diseaseO'CONNOR KEVIN C·Filed 2007·Granted Apr 3, 2012·3 cites·15 claims
- 1571US2025064863A1Vaccination with mica/b alpha 3 domain for the treatment of cancerDANA FARBER CANCER INST INC·Filed 2024·Application pending·0 cites
- 1666US10279021B2Vaccine compositions and methods for restoring NKG2D pathway function against cancersDANA FARBER CANCER INST INC·Filed 2015·Granted May 7, 2019·1 cites·25 claims
- 1765US8119684B2Thiophene derivatives for up-regulating HLA-DM activityYEH LI-AN·Filed 2004·Granted Feb 21, 2012·6 cites·16 claims
- 1859US2008089900A1Identification of self and non-self antigens implicated in autoimmune diseaseHARVARD COLLEGE·Filed 2007·Application pending·0 cites
- 1958US2021299186A1Vaccination with mica/b alpha 3 domain for the treatment of cancerDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 2057US10993971B2Vaccination with MICA/B alpha 3 domain for the treatment of cancerDANA FARBER CANCER INST INC·Filed 2016·Granted May 4, 2021·0 cites·15 claims
- 2156US12018080B2Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathwayBROAD INST INC·Filed 2018·Granted Jun 25, 2024·0 cites·30 claims
- 2256US2005003431A1Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses thereforFiled 2004·Application pending·0 cites
- 2352US10745483B2Therapeutic peptidesDANA-FARBER CANCER INSTITUTE INC·Filed 2014·Granted Aug 18, 2020·0 cites·6 claims
- 2449US2023201166A1Methods for treating cancer by inhibiting carm1DANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 2548US2022363766A1Compositions and methods for treating cytotoxic t cell resistant tumorsDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 2646US2010183658A1Novel Compounds for Enhancing MHC Class II TherapiesBRIGHAM & WOMENS HOSPITAL·Filed 2008·Application pending·0 cites
- 2743US12440451B2Compositions and methods using an epigenetic inhibitorDANA FARBER CANCER INST INC·Filed 2018·Granted Oct 14, 2025·0 cites·8 claims
- 2841US2020179528A9Immune cell-targeted particlesDANA FARBER CANCER INST INC·Filed 2016·Application pending·0 cites
- 2939US11191823B2Compositions and methods for treating arenavirus infectionCHILDRENS MEDICAL CENTER·Filed 2017·Granted Dec 7, 2021·0 cites·19 claims
- 3039US7255861B1Preparations for inducing immunotolerance and uses thereforHARVARD COLLEGE·Filed 1997·Granted Aug 14, 2007·2 cites·2 claims
- 3139US2008194462A1Methods and Compositions for Treatment of Autoimmune DiseasesPEPTIMMUNE INC·Filed 2005·Application pending·0 cites
- 3239US2017198054A1Methods for treating cancer with anti bip or anti mica antibodiesDANA-FARBER CANCER INST·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →